# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹238 Cr** Q4 FY26 * **Gross Profit:** **₹303 Cr** FY26 (+14%) · **₹81 Cr** Q4 FY26 · **34%** Margin * EBITDA: ₹171 Cr FY26 (+23%) · 20% FY26 Margin · ₹40 Cr Q4 FY26 · 17% Q4 Margin * **PAT:** **₹88 Cr** FY26 (+28%) ## B. Profitability & Margin Drivers * **Structural Margin Expansion:** Annual EBITDA growth outpaced revenue, driven by backward integration benefits and favorable product mix. * **Subsidiary Contribution:** Bottom-line performance was bolstered by a **₹14 Cr** sustainable contribution from VKT Pharma, expected to persist through FY27. * **Operating Leverage:** Profitability gains reflect enhanced operating leverage and a transition toward higher-margin internal efficiencies. ## C. Cash Flow & Capital Strategy * **Liquidity Momentum:** Management is prioritizing the strengthening of the Operating Cash Flow (OCF) conversion ratio, which has improved significantly over the **FY23-FY24** baseline. * **Corporate Structure:** Despite operational synergies, there are no immediate plans to merge VKT Pharma or SMS Life Sciences into the parent entity. --- # 2. Product & Therapy Performance ## A. Key Figures * **Revenue:** **₹887 Cr** FY26 (+13%) * **PAT:** **₹102 Cr** FY26 (+47%) · **₹33 Cr** Q4 FY26 * **Product Mix:** **20%** Ibuprofen contribution · **47%** High-value product share * VKT Pharma Contribution: ₹12 Cr to Q4 PAT · ₹40 Cr API sales (SMS to VKT) ## B. Anti-Inflammatory & ARV Segments * **Market Share Expansion:** Robust top-line growth driven by a superior cost structure in ARVs and progressive volume gains in anti-inflammatory APIs. * **Capacity Utilization:** Significant portions of planned capacity for anti-inflammatory products are already committed for the upcoming year. * **Portfolio Diversification:** Launching **four to five new APIs** to enter new therapeutic categories rather than merely expanding existing lines. * **Core Stability:** Anti-erectile dysfunction and anti-ulcer segments remain top-three contributors, with a strategic focus on new product launches within these stable categories. ## C. High-Value API & JV Portfolio * **Mix Optimization:** Management targets increasing high-value product share to **60%** in the medium term as new APIs are integrated into the portfolio. * **Chemo JV Momentum:** Developing **five new high-value products** scheduled for commercialization this fiscal year, leveraging the partner's global reach. * **Strategic Synergies:** Anticipated growth trajectory for JV products mirrors the anti-diabetic segment; VKT Pharma (35% stake) remains a key captive customer for APIs. * **Supply Chain Interdependence:** Procured **₹20 Cr** in intermediates from SMS Life Sciences, maintaining a related-party supply link despite independent corporate structures. ## D. Segment Resource Allocation * **Strategic Pivot:** Proactively shifted resources away from anti-diabetics in Q3 FY26 to prioritize segments with superior unit economics, specifically ARVs and anti-inflammatories. * **Future Growth Engines:** Strategic focus is intensifying on the **CDMO initiative** and **peptide platform**, with a commercial roadmap expected within two quarters. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Brownfield Investment:** **₹280 Cr** Total Outlay · **₹130 Cr** Already Deployed * **Ibuprofen Capacity:** **800 MT/month** FY27 Target · **500 MT/month** Current ## B. Brownfield Expansion Progress * **Strategic Growth:** Significant capital deployment targeting high-margin molecules expected to contribute to the top line in **FY28** with further scaling in **FY29**. ## C. Capacity Utilization & Capex * **Scaling Operations:** Capex is focused on a major capacity hike for Ibuprofen to address rising demand as current facilities approach peak utilization. * **Infrastructure Roadmap:** Total installed capacity is on track for a substantial increase by **FY27**, supporting long-term volume growth. ## D. Backward Integration Benefits * **Margin Protection:** Robust backward integration, particularly in the anti-inflammatory segment, serves as a primary defense against global supply chain volatility and price escalations. * **Vertical Integration Strategy:** Investments in Ibuprofen are dual-purposed to drive both revenue expansion and margin enhancement through deeper vertical integration. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **DMF & CEP Filings:** **12** filed in FY26 · **10** projected for FY27 · **10** projected for FY28 ## B. Pipeline & Infrastructure Development * **High-Value Commercialization:** A dedicated brownfield block is under construction to support the launch of **4 to 5** new high-margin APIs. * **Strategic R&D Trajectory:** Sustained filing momentum underpins a robust pipeline, transitioning from regulatory submission to active commercialization. ## C. Peptide Platform & Future Growth * **Long-term Peptide Optionality:** R&D investments in peptide capabilities are yielding early results, with meaningful revenue contributions anticipated from **FY29 onwards**. * **Margin Expansion Levers:** Introduction of the new API portfolio is identified as the primary catalyst to drive profitability beyond the current **22%** target. --- # 5. Geography & Customer Mix ## A. Key Figures * **Export Contribution:** **70%** of total business * **Customer Concentration:** **28%** of total revenue from top customer * Operational Range: 20% to 25% growth target, conservatively projected lower ## B. Customer Concentration Metrics * **Diversified Single-Client Exposure:** While a significant portion of revenue is tied to one customer, risk is mitigated by a **multi-product supply strategy** rather than single-molecule dependency. * **Backward Integration Benefits:** Internal manufacturing of intermediates has bolstered customer confidence and enabled the firm to capture market price increases, particularly in the **Ibuprofen** segment. ## C. International Market Presence & Share * **Global Revenue Dominance:** The business maintains a heavy international tilt, with the vast majority of turnover derived from export markets. * **Strategic Market Expansion:** Management is targeting incremental growth of **4% to 5%** in specific niches to consolidate market share in key APIs and diversify the portfolio against macro volatility. --- # 6. Pricing & Supply Risks ## A. Key Figures * **Gross Profit Margin:** **2%** decline (QoQ) ## B. Solvent Cost Volatility * **Margin Compression:** Profitability was pressured by a sharp sequential decline in gross margins, primarily triggered by a spike in solvent pricing during March. * **Input Cost Headwinds:** Drastic increases in solvent costs led to elevated raw material consumption expenses, impacting the overall cost structure. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Target:** **15%** FY27 (Conservative) · **20% to 25%** Long-term * **CAPEX Completion:** **March 2027** (FY27) ## B. Revenue & Margin Objectives * **Prudent Near-Term Outlook:** Management maintains a conservative growth stance for the current year, citing **geopolitical uncertainties** in the Middle East and logistics volatility. * **Profitability Benchmarking:** The company aims to return to its historical peak margin levels this year, with further expansion anticipated as operating leverage improves. * **Upside Potential:** Guidance may be exceeded if external supply chain conditions stabilize, supported by a broader product portfolio and recent capability enhancements. ## C. CAPEX & Long-Term Trajectory * **Investment Cycle Maturation:** Significant three-year outlays in **backward integration** and plant engineering are positioned to drive the growth inflection point in FY27 and FY28. * **Revenue Accrual Timeline:** While current projects conclude by the end of FY27, **incremental revenues** from these new capacities are projected to materialize starting in **FY28**.`